FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220797870> ?p ?o ?g. }

• W4220797870 endingPage "62" @default.
• W4220797870 startingPage "58" @default.
• W4220797870 abstract "Drug Resistant -Epilepsy is still a major challenge in pharmacotherapy of epilepsy. Pharmacogenetic pathways are one of the most important elements that can help clinicians determine medication response and provide more efficient drug therapy, especially in cases of drug resistance. Genetic alterations in drug target and transporter proteins, in part, could explain the development of drug-resistant epilepsy. We sought to assess the association of CYP3A5 (rs776746), SCN1A (rs2298771) and ABCG2 (rs2231137) candidate polymorphisms with drug-resistant epilepsy among Iranian children with epilepsy.In a hospital-based case-control study, 93 participants, including 45 men and 48 women aged 1.5 to 14 years old were recruited. Genotyping of CYP3A5 (rs776746), SCN1A (rs2298771) and ABCG2 (rs2231137) polymorphisms using the high-resolution melting (HRM) method were measured in 46 children with drug-resistant epilepsy and 47 healthy control subjects. The binary logistic regression model was used to estimate the odds ratio (OR) for each polymorphism per effect allele increase.The mean (standard deviation [SD]) age of the drug-resistant patients was 10.7 (9.0) years versus 7.3 (3.6) in the control group. In the case group, most of the patients with epilepsy were diagnosed with generalized seizure (about 87%) and negative epileptic history status (63%). Furthermore, idiopathic epilepsy was dominant in the case group (69%). There was a clinically meaningful increase in the chance of drug-resistant epilepsy in participants with candidate polymorphism in ABCG2 gene (per allele T increase, adjusted odds ratio [OR] 2.41, confidence interval [CI] 0.99 to 5.87, P=0.05). No significant association was found between CYP3A5 (per allele C increase, OR 0.92, CI 0.33 to 2.60, P= 0.88) and SCN1A (per allele *1 increase, OR 0.65, 95% CI 0.34 to 1.23, P= 0.19) with drug-resistant epilepsy.We found evidence for the relationship between the ABCG2 gene polymorphism and a higher chance of drug-resistant epilepsy in children. This finding may have important implications for understanding the role of ABCG2 gene polymorphism in children with drug-resistant epilepsy." @default.
• W4220797870 created "2022-04-03" @default.
• W4220797870 creator A5001774598 @default.
• W4220797870 creator A5013627532 @default.
• W4220797870 creator A5029308692 @default.
• W4220797870 creator A5055411940 @default.
• W4220797870 creator A5064838818 @default.
• W4220797870 creator A5079534458 @default.
• W4220797870 creator A5079809830 @default.
• W4220797870 creator A5082677727 @default.
• W4220797870 date "2022-04-01" @default.
• W4220797870 modified "2023-09-30" @default.
• W4220797870 title "ABCG2, SCN1A and CYP3A5 genes polymorphism and drug-resistant epilepsy in children: A case-control study" @default.
• W4220797870 cites W1496902278 @default.
• W4220797870 cites W1506542347 @default.
• W4220797870 cites W1580632486 @default.
• W4220797870 cites W1591367548 @default.
• W4220797870 cites W1920696238 @default.
• W4220797870 cites W1963897559 @default.
• W4220797870 cites W1978839145 @default.
• W4220797870 cites W2010427019 @default.
• W4220797870 cites W2010676165 @default.
• W4220797870 cites W2013533336 @default.
• W4220797870 cites W2023430975 @default.
• W4220797870 cites W2026084712 @default.
• W4220797870 cites W2030655611 @default.
• W4220797870 cites W2039726331 @default.
• W4220797870 cites W2043431574 @default.
• W4220797870 cites W2046259291 @default.
• W4220797870 cites W2072521162 @default.
• W4220797870 cites W2092762612 @default.
• W4220797870 cites W2100663361 @default.
• W4220797870 cites W2107919309 @default.
• W4220797870 cites W2109676467 @default.
• W4220797870 cites W2113524447 @default.
• W4220797870 cites W2115419995 @default.
• W4220797870 cites W2125411036 @default.
• W4220797870 cites W2125519424 @default.
• W4220797870 cites W2130375794 @default.
• W4220797870 cites W2131997198 @default.
• W4220797870 cites W2144296803 @default.
• W4220797870 cites W2164560833 @default.
• W4220797870 cites W2171987398 @default.
• W4220797870 cites W2205252735 @default.
• W4220797870 cites W2226579147 @default.
• W4220797870 cites W2497051257 @default.
• W4220797870 cites W2514842152 @default.
• W4220797870 cites W2569621292 @default.
• W4220797870 cites W2726666234 @default.
• W4220797870 cites W2781510587 @default.
• W4220797870 cites W2791462644 @default.
• W4220797870 cites W2942859808 @default.
• W4220797870 cites W2953483865 @default.
• W4220797870 cites W4211154396 @default.
• W4220797870 doi "https://doi.org/10.1016/j.seizure.2022.03.009" @default.
• W4220797870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35338956" @default.
• W4220797870 hasPublicationYear "2022" @default.
• W4220797870 type Work @default.
• W4220797870 citedByCount "5" @default.
• W4220797870 countsByYear W42207978702022 @default.
• W4220797870 countsByYear W42207978702023 @default.
• W4220797870 crossrefType "journal-article" @default.
• W4220797870 hasAuthorship W4220797870A5001774598 @default.
• W4220797870 hasAuthorship W4220797870A5013627532 @default.
• W4220797870 hasAuthorship W4220797870A5029308692 @default.
• W4220797870 hasAuthorship W4220797870A5055411940 @default.
• W4220797870 hasAuthorship W4220797870A5064838818 @default.
• W4220797870 hasAuthorship W4220797870A5079534458 @default.
• W4220797870 hasAuthorship W4220797870A5079809830 @default.
• W4220797870 hasAuthorship W4220797870A5082677727 @default.
• W4220797870 hasBestOaLocation W42207978701 @default.
• W4220797870 hasConcept C104317684 @default.
• W4220797870 hasConcept C118552586 @default.
• W4220797870 hasConcept C126322002 @default.
• W4220797870 hasConcept C135763542 @default.
• W4220797870 hasConcept C146304588 @default.
• W4220797870 hasConcept C156957248 @default.
• W4220797870 hasConcept C2778186239 @default.
• W4220797870 hasConcept C31467283 @default.
• W4220797870 hasConcept C44249647 @default.
• W4220797870 hasConcept C54355233 @default.
• W4220797870 hasConcept C55775858 @default.
• W4220797870 hasConcept C71924100 @default.
• W4220797870 hasConcept C86803240 @default.
• W4220797870 hasConcept C92137452 @default.
• W4220797870 hasConceptScore W4220797870C104317684 @default.
• W4220797870 hasConceptScore W4220797870C118552586 @default.
• W4220797870 hasConceptScore W4220797870C126322002 @default.
• W4220797870 hasConceptScore W4220797870C135763542 @default.
• W4220797870 hasConceptScore W4220797870C146304588 @default.
• W4220797870 hasConceptScore W4220797870C156957248 @default.
• W4220797870 hasConceptScore W4220797870C2778186239 @default.
• W4220797870 hasConceptScore W4220797870C31467283 @default.
• W4220797870 hasConceptScore W4220797870C44249647 @default.
• W4220797870 hasConceptScore W4220797870C54355233 @default.
• W4220797870 hasConceptScore W4220797870C55775858 @default.
• W4220797870 hasConceptScore W4220797870C71924100 @default.
• W4220797870 hasConceptScore W4220797870C86803240 @default.

• next